Total Funding
66
58
Total FundingPost-IPO Equity raised
Growth Score
-16 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
64162
Biodexa Pharmaceuticals is a pharmaceutical company focused on particle engineering with an emphasis on microfluidics and drug delivery.
- Dmitry Zamoryakhin: Chief Scientific Officer
- Fiona Sharp: Chief Financial Officer and Company SecretaryPast Role: Biodexa Pharmaceuticals, Group Financial Controller
About the Company
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through
strategic acquisitions.
